Breaking News

Immune Pharma Gains Exclusive License to Antibody Technology

December 29, 2015

Bispecific antibody demonstrated direct anti-cancer effects in vitro and in vivo

Immune Pharmaceuticals has entered into an exclusive license with Atlante Biotech SAS, for the patents and know-how for a new format of bispecific antibodies.
 
Recent data on the platform prototype bispecific antibody was shown to retain effector functions and mediate redirect killing of target cells by cytokine induced killer T cells. The bispecific antibody demonstrated direct anti-cancer effects in vitro, as well as in vivo anti-tumor activity and improved survival in a mouse xenograft model of disseminated leukemia.  
 
The R&D work on the bispecific antibodies will be performed in Immune's recently established Immunology R&D unit at the Alexandria Center for Life Sciences in New York, under Dr. Boris Shor, executive director of R&D, who joined the company from Pfizer Oncology.
 
Dr. Daniel Teper, chief executive officer of Immune said, "This is an important milestone as we make progress with our immuno-oncology pipeline. Our research will focus on the application of this novel bispecific platform to target immune checkpoints.  Our plan is to generate additional pre-clinical data with selected bispecific drug candidates in 2016."
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems